Systemic sclerosis & Raynaud's
Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease
Authors' conclusion
Prediction of the progression of SSc-ILD may require different approaches in distinct subgroups of patients.
Study context
- Population
- Patients with SSc-ILD in the placebo group of the SENSCIS trialSENSCIS placebo group
- Participants
- 288 vs 155
- Comparison
- Overall placebo vs Early/inflammatory SSc and/or severe skin fibrosis
- Overall placebon = 288
- Early/inflammatory SSc and/or severe skin fibrosisn = 155
- Primary endpoint
- Progression of SSc-ILD (absolute decline in forced vital capacity (FVC) % predicted >5% or death)
- Follow-up
- 52 weeks
Methodological detailssecondary analysis of the SENSCIS trial placebo group, logistic regression, multivariable model, apparent AUC
- Secondary analysis of the SENSCIS trial placebo group
- Logistic regression
- Multivariable model
- Apparent AUC
Primary result
As reported in the abstract
Performance of final multivariable model for predicting SSc-ILD progression
| Group | Apparent AUC |
|---|---|
| Overall placebo | 0.63 |
| Early/inflammatory SSc and/or severe skin fibrosis | 0.75 |
Apparent AUC
Overall placebo0.63
Early/inflammatory SSc and/or severe skin fibrosis0.75
Original publication
Development of a multivariable prediction model for progression of systemic sclerosis-associated interstitial lung disease. RMD Open. Published 5 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →